Lecturer
School of Pharmacy
Dept. of Pharmacology & Therapeutics
Cavanagh Pharmacy Building
College Road

T: +353-21-4901665
F: +353-21-4901656
E: anne.moore@ucc.ie
W: http://www.immupatch.com

Dr. Anne Moore graduated with a degree in Biochemistry University College Cork. She completed a PhD in HIV vaccine immunology with Professor Kingston Mills. Dr. Moore subsequently embarked upon post-doctoral work on defects in immune responses in HIV-infected individuals in the Wistar Institute in Philadelphia and further work on recombinant vaccines against viruses such as HIV and Ebola virus in Dr. Gary Nabel's lab then at the University of Michigan. As a senior immunologist in Prof. Adrian Hill's group in the University of Oxford, she developed several T cell inducing vaccine candidates against malaria and TB and was involved in clinical trials of these and other vaccine candidates in Oxford and malaria endemic areas in Africa. She took up a position as a Lecturer in Pharmacology, based in the School of Pharmacy, UCC in early 2007.

Research Interests

The central aim of Dr. Moore’s group is to develop and translate innovative vaccines and immune-related therapies. Our research extends from basic cellular immunology to clinical translation with the aim of improving vaccine efficacy, immunization logistics and therapeutic strategies.

IMMUPATCH DELIVERY TECHNOLOGY

ImmuPatch is a microneedle-based platform technology for transcutaneous drug and vaccine delivery that has been developed to overcome current technical, financial and logistical obstacles to drug and vaccine delivery. Microneedles are micron-scale protrusions that penetrate into skin creating conduits for vaccine administration. Our microneedle patches consist of arrays of micron-scale projections ranging in height typically from 50-600 micrometres.

Currently, all vaccines must be stored in refrigerated or frozen conditions. Such narrow low temperature ranges requires a highly organised, expensive and complicated supply system, termed ‘cold-chain’. This is unsustainable. Secondly, there are a large number of problems associated with injection by parenteral routes including difficulty of use, particularly with intradermal injection; patient acceptability and compliance; pain and fear of needles; hazardous sharps-waste; accidental needle stick injuries; requirement for trained personnel to correctly reconstitute drug/vaccine to liquid form and correctly inject to indicated site. ImmuPatch is being designed to provide the convenience of self-administration in a small, low-cost system. It addresses several issues relating to drug and vaccine stability, distribution (pharmacological and logisitcal) and efficacy.

We developed three defined, complementary streams, using silicon, coated or dissolvable microneedles.

Silicon microneedle patches: We demonstrated proof-of-concept with several vaccine types including live, inactivated and subunit vaccines. As these are examples of the majority of licensed vaccine types, these studies exemplify the breadth of use of silicon microneedles for immunization purposes.

Coated microneedle patches: The next development was to combine the drug and the patch to develop a single product that stabilised the drug/vaccine in a dry form onto silicon microneedles. We developed a novel process, based on spraying, for coating microneedle arrays. We developed a method of concentrating the active material on and around the shaft of the microneedle and not onto the base of the array. We demonstrated that coated microneedle patches induced an antibody response that was equivalent to that induced by intradermal vaccination.

 Dissolvable ImmuPatch: The final innovation was to completely fabricate the microneedle from the formulated drug. The structure and material of construction of dissolvable microneedles enables the stratum corneum to be penetrated. Once the microneedle has inserted into the skin it dissolves, thereby delivering the drug/vaccine to the body. Instead of conventional fill/finish into vials or pre-filled syringes for injection with a needle and syringe, the active material is formulated into dissolvable microneedle patches that are administered into the skin.  Dissolvable microneedles permit higher dose-loading, enhanced stability outside of cold chain, complete microneedle dissolution in skin and potential lower costs of materials and simplicity of production compared to other microneedle systems. Complete dissolution of the microneedle in the skin has a number of advantages including removing the requirement of hazardous waste disposal, simple application, therefore improving patient compliance and acceptability and lack of requirement of prior reconstitution. We developed two novel processes to produce DMN which are unique to the ImmuPatch team and are being patent protected. We demonstrated that DMN produced by both methods are mechanically strong with excellent skin penetration properties, they stabilise sensitive live vaccines for greater than 6 months and DMN loaded with vaccine induce antibody and T cell responses.

Our current research focus is to determine the breadth of use of dissolvable microneedle patches for vaccine and drug delivery and the extent of the enhancement of stability, potency and efficacy of a range of drugs or vaccines in these patches. Specifically, we are interested in understanding (i) how the process and formulation can be optimised to produce physically, chemically and immunologically stable drug and vaccine-loaded DMN patches;(ii) the range of novel and licensed vaccine adjuvants that can be incorporated into microneedle patches and (iii) how and why delivery of drugs and vaccines into the skin modulates the quantity and quality of the immune response and the distribution of drug within the body.

 HUMAN AND VETERINARY VACCINE DEVELOPMENT

In collaboration with the Jenner Institute, University of Oxford, we developed a T cell-inducing universal influenza virus vaccine that protects against multiple strains of the virus that cause both seasonal and pandemic infections in human and veterinary species. We demonstrated that this strategy protects against challenge by multiple influenza virus strains. This vaccine is being clincally tested by the Jenner Institute. Work within our group defined pre-clinical correlates of protective systemic and mucosal immunity. We are also interested in further understanding antibody and T cell responses induced by candidate malaria vaccines in collaboration with the Jenner Institute. Finally, we are examining the induction of mucosal immunity in pre-clinical models by vaccines containing novel adjuvants.

IL-2:

We previously demonstrated that a monoclonal antibody to the IL-2 receptor subunit, CD25, augments vaccine-induced immunity in mice and it safely and significantly increased vaccine immunogenicity in non-human primates. Based on our previous work and in collaboration with researchers at Trinity College Dublin, we developed a novel method of inhibiting IL-2/CD25 interaction, independently of monoclonal antibodies and we are further exploring the modulation by CD25 of the immune system. We also examined the role of soluble CD25 in modulating auto-immune disorders.

 

Peer Reviewed Journals

YearPublication
(2014)'Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route'
Carey, JB,Vrdoljak, A,O'Mahony, C,Hill, AVS,Draper, SJ,Moore, AC (2014) 'Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route'. Scientific Reports, 4 [DOI] [Details]
(2014)'Enhancement of the in vitro penetration of quercetin through pig skin by combined microneedles and lipid microparticles'
Paleco R., Vučen S.R., Crean A.M., Moore A.C., Scalia S (2014) 'Enhancement of the in vitro penetration of quercetin through pig skin by combined microneedles and lipid microparticles'. International Journal of Pharmaceutics, [DOI] [Details]
(2013)'Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1'
Lambe, T,Carey, JB,Li, YY,Spencer, AJ,van Laarhoven, A,Mullarkey, CE,Vrdoljak, A,Moore, AC,Gilbert, SC (2013) 'Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1'. Scientific Reports, 3 [DOI] [Details]
(2013)'The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment'
Goodman AL, Forbes EK, Williams AR, Douglas AD, de Cassan SC, Bauza K, Biswas S, Dicks MD, Llewellyn D, Moore AC, Janse CJ, Franke-Fayard BM, Gilbert SC, Hill AV, Pleass RJ, Draper SJ. (2013) 'The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment'. Scientific Reports, 3 Globe icon [DOI] [Details]
(2013)'Production of dissolvable microneedles using an atomised spray process: Effect of microneedle composition on skin penetration'
McGrath MG, Vucen S, Vrdoljak A, Kelly A, O'Mahony C, Crean AM, Moore AC. (2013) 'Production of dissolvable microneedles using an atomised spray process: Effect of microneedle composition on skin penetration'. European Journal of Pharmaceutical Science, Epub ahead of print Globe icon [DOI] [Details]
(2013)'Improved percutaneous delivery of ketoprofen using combined application of nanocarriers and silicon microneedles'
Sonja R. Vucˇen, Gordana Vulet, Abina M. Crean, Anne C. Moore, Nenad Ignjatovic´and Dragan Uskokovic´ (2013) 'Improved percutaneous delivery of ketoprofen using combined application of nanocarriers and silicon microneedles'. Journal of Pharmacy and Pharmacology, 65 (8) Globe icon [DOI] [Details]
(2013)'Improved percutaneous delivery of ketoprofen using combined application of nanocarriers and silicon microneedles'
Vucen, SR,Vuleta, G,Crean, AM,Moore, AC,Ignjatovic, N,Uskokovic, D (2013) 'Improved percutaneous delivery of ketoprofen using combined application of nanocarriers and silicon microneedles'. Journal of Pharmacy and Pharmacology, 65 :1451-1462 [DOI] [Details]
(2012)'Coated microneedle arrays for transcutaneous delivery of live virus vaccines'
Vrdoljak, A.,McGrath, M. G.,Carey, J. B.,Draper, S. J.,Hill, A. V.,O'Mahony, C.,Crean, A. M.,Moore, A. C. (2012) 'Coated microneedle arrays for transcutaneous delivery of live virus vaccines'. Journal of Controlled Release, 159 (11):34-4234 Globe icon [Details]
(2012)'Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications'
Galvin P, Thompson D, Ryan K.B., McCarthy A, Moore AC, Burke CS, Dyson M, Maccraith BD, Gun'ko YK, Byrne MT, Volkov Y, Keely C, Keehan E, Howe M, Duffy C, Macloughlin R. (2012) 'Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications'. Cellular and molecular life sciences : CMLS, 69 (3):389-404 [DOI] [Details]
(2012)'Coated microneedle arrays for transcutaneous delivery of live virus vaccines'
Vrdoljak, A,McGrath, MG,Carey, JB,Draper, SJ,Hill, AVS,O'Mahony, C,Crean, AM,Moore, AC (2012) 'Coated microneedle arrays for transcutaneous delivery of live virus vaccines'. Journal of controlled release : official journal of the Controlled Release Society, 159 (1):34-42 [DOI] [Details]
(2012)'Soluble IL-2Rα (sCD25) Exacerbates Autoimmunity and Enhances the Development of Th17 Responses in Mice'
Russell SE, Moore AC, Fallon PG, Walsh PT. (2012) 'Soluble IL-2Rα (sCD25) Exacerbates Autoimmunity and Enhances the Development of Th17 Responses in Mice'. Plos One, 7 (10) [DOI] [Details]
(2012)'Soluble IL-2R alpha (sCD25) Exacerbates Autoimmunity and Enhances the Development of Th17 Responses in Mice'
Russell, SE,Moore, AC,Fallon, PG,Walsh, PT (2012) 'Soluble IL-2R alpha (sCD25) Exacerbates Autoimmunity and Enhances the Development of Th17 Responses in Mice'. Plos One, 7 [DOI] [Details]
(2011)'Microneedle Array Design Determines the Induction of Protective Memory CD8(+) T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice'
Carey, JB,Pearson, FE,Vrdoljak, A,McGrath, MG,Crean, AM,Walsh, PT,Doody, T,O'Mahony, C,Hill, AVS,Moore, AC; (2011) 'Microneedle Array Design Determines the Induction of Protective Memory CD8(+) T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice'. Plos One, 6 [DOI] [Details]
(2011)'Determination of parameters for successful spray coating of silicon microneedle arrays'
McGrath MG, Vrdoljak A, O'Mahony C, Oliveira JC, Moore AC, Crean AM; (2011) 'Determination of parameters for successful spray coating of silicon microneedle arrays'. International Journal of Pharmaceutics, 415 :140-149 [DOI] [Full Text] [Details]
(2011)'Microneedle Array Design Determines the Induction of Protective Memory CD8(+) T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice'
Carey, J. B.,Pearson, F. E.,Vrdoljak, A.,McGrath, M. G.,Crean, A. M.,Walsh, P. T.,Doody, T.,O'Mahony, C.,Hill, A. V. S.,Moore, A. C. (2011) 'Microneedle Array Design Determines the Induction of Protective Memory CD8(+) T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice'. Plos One, 6 (77) Globe icon [Details]
(2010)'Development of stabilized vaccines with needle-free devices for targeted skin immunization'
Moore, A. C., Crean, A. M., O¿Mahony; (2010) 'Development of stabilized vaccines with needle-free devices for targeted skin immunization'. European Pharmaceutical Review, 15 (6):56-60 Globe icon [Full Text] [Details]
(2009)'Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria'
Draper SJ, Goodman AL, Biswas S, Forbes EK, Moore AC, Gilbert SC, Hill AV; (2009) 'Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria'. Cell Host and Microbe, 5 (1):95-105 Globe icon [DOI] [Details]
(2008)'Single dose protection against P. berghei by Simian Adenoviral vector using human CMV promoter containing Intron A'
Sridhar S., Reyes-Sandoval A., Draper S.J., Moore A.C., Gilbert S.C., Gao G.P., Wilson J.M. and Hill A.V.S. ; (2008) 'Single dose protection against P. berghei by Simian Adenoviral vector using human CMV promoter containing Intron A'. Journal of Virology, (82):3822-3833 Globe icon [Details]
(2008)'Multi-Stage Protection against Malaria using Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1'
Draper S.J, Moore A.C., Goodman A.L., Long C.A., Holder A.A., Gilbert S.C., Hill F., Hill A.V.S.; (2008) 'Multi-Stage Protection against Malaria using Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1'. Nature medicine, (14):819-821 Globe icon [DOI] [Details]
(2008)'Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria'
Schmidt NW, Podyminogin RL, Butler NS, Badovinac VP, Tucker BJ, Bahjat KS, Lauer P, Reyes-Sandoval A, Hutchings CL, Moore AC, Gilbert SC, Hill AV, Bartholomay LC, Harty JT.; (2008) 'Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria'. Proceedings of The National Academy of Sciences of The United States of America, 105 (37):14017-14022 Globe icon [DOI] [Details]
(2008)'Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei'
Reyes-Sandoval A., Sridhar S., Berthoud T., Moore A.C., Harty J.T., Gilbert S.C., Gao G.P., Ertl H.C., Wilson J.M. and Hill A.V.S. ; (2008) 'Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei'. European Journal of Immunology, (38):732-741 Globe icon [DOI] [Details]
(2007)'Combination Vaccines; synergistic simultaneous induction of antibody and T cell immunity results in enhanced vaccine efficacy'
Moore A.C. Hutchings C.L.; (2007) 'Combination Vaccines; synergistic simultaneous induction of antibody and T cell immunity results in enhanced vaccine efficacy'. Expert Review of Vaccines, 6 (1):111-121 Globe icon [DOI] [Details]
(2007)'Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge'
Hutchings C.L, Birkett A.J., Moore A.C., and Hill A.V.S. ; (2007) 'Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge'. Infection and Immunity, (95):5819-5826 Globe icon [DOI] [Details]
(2006)'Safety, immunogenicity and efficacy of prime-boost immunization with recombinant pox viruses FP9 and modified vaccinia virus Ankara encoding the full length P. falciparum - circumsporozoite protein'
Walther M., Thompson F., Dunachie S., Keating M., Todryk S., Berthoud T., Andrews L., Andersen R., Moore A.C., Gilbert S.C., Poulton I., Dubovsky F., Tierney E., Correa S., Huntcooke A., Butcher G., Williams J., Sinden R.E., Hill A.V.S.; (2006) 'Safety, immunogenicity and efficacy of prime-boost immunization with recombinant pox viruses FP9 and modified vaccinia virus Ankara encoding the full length P. falciparum - circumsporozoite protein'. Infection and Immunity, (74):2706-2716 Globe icon [DOI] [Details]
(2006)'Safety of Recombinant Fowlpox Strain 9 and Modified Vaccinia Virus Ankara Vaccines Against Liver-Stage P. falciparum Malaria in Non-Immune Volunteers'
Webster D.P., Dunachie S., McConkey S., Poulton I., Moore A.C., Walther M., Laidlaw S.M., Peto T., Skinner M.A., Gilbert S. C., Hill A.V.S.; (2006) 'Safety of Recombinant Fowlpox Strain 9 and Modified Vaccinia Virus Ankara Vaccines Against Liver-Stage P. falciparum Malaria in Non-Immune Volunteers'. Vaccine, (24):3026-3034 Globe icon [DOI] [Details]
(2005)'Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced Immunodominance'
Moore A.C., Gallimore A., Draper S., Watkins K.R., Gilbert S.C. and Hill A.V.S. ; (2005) 'Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced Immunodominance'. Journal of Immunology, (175):7264-7273 Globe icon [Details]
(2005)'Novel Protein and Poxvirus Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell Mediated Immunity'
Hutchings C.L, Gilbert S.C., Hill A.V.S and Moore A.C.; (2005) 'Novel Protein and Poxvirus Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell Mediated Immunity'. Journal of Immunology, (175):599-606 Globe icon [Details]
(2004)'Progress in DNA-based heterologous prime-boost immunization strategies for malaria'
Moore AC, Hill AV; (2004) 'Progress in DNA-based heterologous prime-boost immunization strategies for malaria'. Immunological reviews, 199 :126-143 Globe icon [DOI] [Details]
(2004)'A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses'
Prieur E, Gilbert S.C., Schneider J ., Moore A.C. , Sheu E.G, Goonetilleke N., Robson K.J.H., and Hill A.V. ; (2004) 'A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses'. Proceedings of The National Academy of Sciences of The United States of America, (101):290-295 Globe icon [DOI] [Details]
(2004)'Splenic dendritic cell subsets prime and boost CD8 T cells and are involved in the generation of effector CD8 T cells'
Behboudi S., Moore A.C. and Hill A.V.S. ; (2004) 'Splenic dendritic cell subsets prime and boost CD8 T cells and are involved in the generation of effector CD8 T cells'. Cellular Immunology, (228):15-19 Globe icon [DOI] [Details]
(2004)'Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction'
Behboudi S., Moore A.C., Gilbert S., Nicoll C.L. and Hill A.V.S. ; (2004) 'Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction'. Vaccine, 22 :4326-4331 Globe icon [DOI] [Details]
(2002)'Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice'
Moore AC, Kong WP, Chakrabarti BK, Nabel GJ; (2002) 'Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice'. Journal of virology, 76 (1):243-250 Globe icon [DOI] [Details]
(2000)'Inhibition of Interleukin-12 production in human monocyte-derived macrophages by Tumor Necrosis Factor'
Ma X., Sun J., Papasavvas E., Riemann H., Robertson S., Marshall J., Bailer R.T., Moore A.C., Donnelly R., Trinchieri G., Montaner L.J.,; (2000) 'Inhibition of Interleukin-12 production in human monocyte-derived macrophages by Tumor Necrosis Factor'. Journal of Immunology, 164 :1722-1729 Globe icon [Details]
(1999)'The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1'
Moore A, McCarthy L, Mills KH; (1999) 'The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1'. Vaccine, 17 (20-21):2517-2527 [Details]
(1998)'Approaches to new vaccines'
Mahon BP, Moore A, Johnson PA, Mills KH.; (1998) 'Approaches to new vaccines'. Critical Review of Biotechnology, 18 (4):257-282 [Details]
(1995)'An adjuvant formulation that switches Th2 to Th1 responses with soluble recombinant HIV proteins'
Moore A, Adams S., Garcon N., Delchambre M., Thriart C., Bruck C. and Mills KH.; (1995) 'An adjuvant formulation that switches Th2 to Th1 responses with soluble recombinant HIV proteins'. Immunology, 86 [Details]
(1995)'Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells'
Moore A, McGuirk P, Adams S, Jones WC, McGee JP, O'Hagan DT, Mills KH.; (1995) 'Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells'. Vaccine, 13 (18):1741-1749 [Details]
(1994)'Factors affecting Th1 and Th2 cell induction and immunoglobulin class switching in the immune response to HIV proteins'
Moore A.C., Adams S., and Mills K.H.G.; (1994) 'Factors affecting Th1 and Th2 cell induction and immunoglobulin class switching in the immune response to HIV proteins'. Immunology, 83, S1 [Details]

Other Journals

YearPublication
(2010)'Development of Stabilised Vaccines with Needle-Free Devices for Targeted Skin Immunization'
A. Crean, C. O’Mahony and A. C. Moore (2010) 'Development of Stabilised Vaccines with Needle-Free Devices for Targeted Skin Immunization' European Pharmaceutical Review, 15 (6) :56-60. [Details]

Conference Publications

YearPublication
(2013)35th All-Ireland Schools of Pharmacy Conference
Allen, E.,Crean, A.,O’Mahony, C.,Moore, A. C. (2013) Influenza Vaccination using Dissolvable ImmuPatchInfluenza Vaccination using Dissolvable ImmuPatch 35th All-Ireland Schools of Pharmacy Conference Belfast, UK, [Details]
(2012)2nd International Conference on Microneedles: Microneedles 2012
A. M. Crean, M. G. McGrath, C. O’Mahony, A. Vrdoljak and A. C. Moore (2012) Dissolvable ImmuPatch Microneedles for Drug Delivery 2nd International Conference on Microneedles: Microneedles 2012 Cork, , 13-MAY-12 - 15-MAY-12 [Details]
(2011)38th Annual Meeting and Exposition of the Controlled Release Society
McGrath, M. G.,O'Mahony, C.,Vrdoljak, A.,Moore, A. C.,Crean, A. (2011) Design of Dissolvable Microneedles for Drug DeliveryDesign of Dissolvable Microneedles for Drug Delivery 38th Annual Meeting and Exposition of the Controlled Release Society Maryland, USA, [Details]
(2011)38th Annual Meeting and Exposition of the Controlled Release Society38th Annual Meeting and Exposition of the Controlled Release Society
Carey, J. B.,Pearson, F. E.,Vrdoljak, A.,Crean, A.,O'Mahony, C.,Hill, A. V. S.,Moore, A. C. (2011) Immunization using ImmuPatch silicon microneedles results in enhanced T-cell and antibody responses compare to traditional imunization routesImmunization using ImmuPatch silicon microneedles results in enhanced T-cell and antibody responses compare to traditional imunization routes 38th Annual Meeting and Exposition of the Controlled Release Society38th Annual Meeting and Exposition of the Controlled Release Society Maryland, USAMaryland, USA, [Details]
(2011)Skin Vaccination Summit 2011
Moore, A. C.,Pearson, F.,Vrdoljak, A.,McGrath, M. G.,Draper, S.,Hill, A. V. S.,Crean, A.,O'Mahony, C. (2011) ces for vaccination Skin Vaccination Summit 2011 Washington, USA, , 11-OCT-11 [Details]
(2011)Skin Vaccination Summit 2011Skin Vaccination Summit 2011
O'Mahony, C.,Moore, A. C.,Blake, A.,Scully, J.,O'Brien, J.,Hegarty, M. (2011) Silicon microneedles for vaccine deliverySilicon microneedles for vaccine delivery Skin Vaccination Summit 2011Skin Vaccination Summit 2011 Washington, USAWashington, USA, [Details]
(2011)38th Annual Meeting and Exposition of the Controlled Release Society
Vrdoljak, A.,McGrath, M. G.,Crean, A.,O'Mahony, C.,Moore, A. C. (2011) Development of ImmuPatch arrays coated with live vaccine 38th Annual Meeting and Exposition of the Controlled Release Society Maryland, USA, [Details]
(2011)38th Annual Meeting Controlled Release Society
John B. Carey, Frances E. Pearson, Anto Vrdoljak, Abina M. Crean, Conor O¿Mahony, Adrian V.S. Hill, Anne C. Moore; (2011) Immunization using ImmuPatch Silicon Microneedle Arrays results in Enhanced T 38th Annual Meeting Controlled Release Society National Harbor, Maryland, U.S.A, [Details]
(2011)38th Annual Meeting Controlled Release Society
M.G. McGrath, C.O¿Mahony, A. Vrdoljak, A.C. Moore, A.M. Crean; (2011) Design of Dissolvable Microneedles for Drug Delivery 38th Annual Meeting Controlled Release Society National Harbor, Maryland, U.S.A, [Details]
(2010)12th International Conference on Perspectives in Percutaneous Penetration
M. G. McGrath, C. O¿Mahony, J. B. Carey, A. Vrdoljak, A. C. Moore and A. M. Crean; (2010) Spray Coating of Silicon Microneedle Patches for Intradermal Drug Delivery 12th International Conference on Perspectives in Percutaneous Penetration [Details]
(2010)Perspectives in Percutaneous Penetreation
McGrath M., O¿Mahony C., Carey J.B., Vrdoljak A., Moore A.C. and Crean A; (2010) Spray Coating of Silicon Microneedle Patches for Intradermal Drug Delivery Perspectives in Percutaneous Penetreation La Grande Motte, France, , 06-APR-10 - 08-APR-10 [Details]
(2010)Modern Mucosal Vaccines and Adjuvants
Moore A.C., Carey J.B, Pearson F.E., Vrdoljak A., McGrath M., Draper S.J., Gilbert S.C., Hill A.V.S., Crean A. and O¿Mahony C. ; (2010) Enhanced T cell and Antibody Responses induced by ImmuPatch Transdermal Vaccination Modern Mucosal Vaccines and Adjuvants Dublin, Ireland, , 28-APR-10 - 30-APR-10 [Details]
(2010)Microneedles 2010Microneedles 2010
Pearson, F. E.,Reyes-Sandoval, A.,O'Mahony, C.,Moore, A. C.,Hill, A. V. S. (2010) Delivery of Recombinant Adenoviral Vector malaria vaccines by ImmuPatch Induces Protective CD8+ T-cell Mediated Immunity Against Parasite ChallengeDelivery of Recombinant Adenoviral Vector malaria vaccines by ImmuPatch Induces Protective CD8+ T-cell Mediated Immunity Against Parasite Challenge Microneedles 2010Microneedles 2010 Atlanta, USAAtlanta, USA, [Details]
(2010)Perspectives in Percutaneous Penetration (PPP 2010)Perspectives in Percutaneous Penetration (PPP 2010)
O'Mahony, C.,Blake, A.,Scully, J.,O'Brien, J.,Moore, A. C. (2010) Silicon Microneedles for Painless Percutaneous PenetrationSilicon Microneedles for Painless Percutaneous Penetration Perspectives in Percutaneous Penetration (PPP 2010)Perspectives in Percutaneous Penetration (PPP 2010) La Grande Motte, FranceLa Grande Motte, France, [Details]
(2010)Molecules to Medicine Conference 2010Molecules to Medicine Conference 2010
O'Mahony, C.,Blake, A.,Scully, J.,O'Brien, J.,Moore, A. C. (2010) Silicon Microneedles for Painless Percutaneous PenetrationSilicon Microneedles for Painless Percutaneous Penetration Molecules to Medicine Conference 2010Molecules to Medicine Conference 2010 Cork, IrelandCork, Ireland, [Details]
(2010)MMVAM 2010
Moore, A. C.,Carey, J. B.,Pearson, F. E.,Vrdoljak, A.,McGrath, M. G.,Draper, S. J.,Gilbert, S. C.,Hill, A. V. S.,Crean, A.,O'Mahony, C. (2010) Enhanced T-cell and Antibody Responses Induced by ImmuPatch Transdermal Vaccination MMVAM 2010 Dublin, IrelandDublin, Ireland, [Details]
(2010)Microneedles 2010Microneedles 2010
Moore, A. C.,Carey, J. B.,Pearson, F. E.,Vrdoljak, A.,McGrath, M. G.,Draper, S. J.,Gilbert, S. C.,Hill, A. V. S.,Crean, A.,O'Mahony, C. (2010) Enhanced Immune Responses Induced by ImmuPatch Transcutaneous VaccinationEnhanced Immune Responses Induced by ImmuPatch Transcutaneous Vaccination Microneedles 2010Microneedles 2010 Atlanta, USAAtlanta, USA, [Details]
(2010)4th Vaccine and ISV Annual Global Congress4th Vaccine and ISV Annual Global Congress
Moore, A. C.,Carey, J. B.,Crean, A.,Vrdoljak, A.,McGrath, M. G.,O'Mahony, C. (2010) Percutaneous Immunization using ImmuPatch: Needle-free vaccination that results in stronger T-cell and antibody responses compared to traditional immunization routes 4th Vaccine and ISV Annual Global Congress4th Vaccine and ISV Annual Global Congress Vienna, Austria, [Details]
(2010)Microneedles 2010Microneedles 2010
McGrath, M. G.,Vrdoljak, A.,O'Mahony, C.,Carey, J. B.,Moore, A. C.,Crean, A. (2010) Percutaneous vaccine Delivery Using MicroneedlesPercutaneous vaccine Delivery Using Microneedles Microneedles 2010Microneedles 2010 Atlanta, USAAtlanta, USA, [Details]
(2010)Perspectives in Percutaneous Penetreation
Moore A.C., Carey J.B., McGrath M. Pearson F.E., Vrdoljak A. Hill A.V.S., Crean A. and O¿Mahony C. ; (2010) Percutaneous immununization using ImmuPatch: Comparison of vaccine localisation and induction of antibody and T cell responses in a pre-clinical model Perspectives in Percutaneous Penetreation La Grande Motte, France, , 06-APR-10 - 10-APR-10 [Details]
(2010)Molecules to Medicine Conference 2010Molecules to Medicine Conference 2010
Carey, J. B.,Moore, A. C.,McGrath, M. G.,Pearson, F.,Hill, A. V. S.,Moore, A. C. (2010) Percutaneous Immunization using Immupatch; Comparison of Vaccine Localisation and Induction of Antibody and T-cell responses in a Pre-clinical ModelPercutaneous Immunization using Immupatch; Comparison of Vaccine Localisation and Induction of Antibody and T-cell responses in a Pre-clinical Model Molecules to Medicine Conference 2010Molecules to Medicine Conference 2010 Cork, IrelandCork, Ireland, [Details]
(2010)Perspectives in Percutaneous Penetration (PPP 2010)
McGrath, M. G.,O'Mahony, C.,Carey, J. B.,Vrdoljak, A.,Moore, A. C.,Crean, A. (2010) Percutaneous Immunization Using ImmuPatch: Comparison of Vaccine Localisation and Induction of Antibody and T-cell responses in a Pre-clinical Model Perspectives in Percutaneous Penetration (PPP 2010) La Grande Motte, France, [Details]
(2010)First International Conference on Microneedles
Moore A.C., Carey J.B., Pearson F., Vrdoljak A., McGrath M., Draper S.J., Gilbert S.C., Hill A.V.S., Crean A. and O¿Mahony C., ; (2010) Enhanced Immune Responses induced by ImmuPatch Transcutaneous Vaccination First International Conference on Microneedles Atlanta, Georgia, , 24-MAY-10 - 26-MAY-10 [Details]
(2010)First International Conference on Microneedles
Moore A.C., Carey J.B., Pearson F., Vrdoljak A., McGrath M., Draper S.J., Gilbert S.C., Hill A.V.S., Crean A. and O¿Mahony C., ; (2010) Enhanced Immune Responses induced by ImmuPatch Transcutaneous Vaccination First International Conference on Microneedles Atlanta, Georgia, , 24-MAY-10 - 26-MAY-10 [Details]
(2010)First International Conference on Microneedles
McGrath M., Vrdoljak A., O¿Mahony C., Carey J.B., Moore A.C. and Crean A.; (2010) Percutaneous Vaccine Delivery Using Microneedles First International Conference on Microneedles Atlanta, Georgia, , 24-MAY-10 - 26-APR-10 [Details]
(2010)First International Conference on Microneedles
McGrath M., Vrdoljak A., O¿Mahony C., Carey J.B., Moore A.C. and Crean A.; (2010) Percutaneous Vaccine Delivery Using Microneedles First International Conference on Microneedles Atlanta, Georgia, , 24-MAY-10 - 26-APR-10 [Details]
(2010)4th Vaccine and ISV Annual Global Congress
A.C. Moore, J. Carey, F. Pearson, A. Vrdoljak, M. McGrath, S. Draper, S. Gilbert, A. Hill, A. Crean and C. O¿Mahony; (2010) Percutaneous Immunization using ImmuPatch: Needle-free vaccination that results in stronger T cell and antibody responses compared to traditional immunization routes 4th Vaccine and ISV Annual Global Congress Vienna, Austria, , 03-OCT-10 - 05-OCT-10 [Details]

Published Reports

YearPublication
(2006)The use of non-human primates in research, chaired by Sir David Weatherall. Report to Wellcome Trust, MRC, Academy of Medical Sciences, The Royal Society.
Sir David Weatherall; (2006) The use of non-human primates in research, chaired by Sir David Weatherall. Report to Wellcome Trust, MRC, Academy of Medical Sciences, The Royal Society. Wellcome Trust, MRC, The Royal Society, UK. [Details]

Honours and Awards

 YearTitleAwarding Body
2013Joint Winner "Get Started Technology Venture Programme" SFI
2012UCC Research Team of the Year UCC

Professional Associations

 AssociationFunctionFrom / To
Burroughs-Wellcome sponsored; "Malaria Liver-stage Genomics and Proteomics", Washington DC Contributor/
"The use of non-human primates in research", chaired by Sir David Weatherall. Report to Wellcome Trust, MRC, Academy of Medical Sciences, The Royal Society Consultee to the working group/
Livestock Vaccine Enterprise Initiative Meeting, Wellcome Trust Centre for Human Genetics Invited delegate to initiate international veterinary vaccine consortium17-MAY-07 / 18-MAY-07
New Trends in Cancer Immunotherapy. Fondation Merieux Invited Participant08-JUL-07 / 11-JUL-07

Patents

 Patent NumberTitleInventorGranted
WO2004110482Combination Vaccines Moore A.C., Nicoll C.L, Hill A.V.S26-OCT-06
WO2005115451METHODS FOR GENERATING IMPROVED IMMUNE RESPONSE MOORE ANNE CLARE; HILL ADRIAN V S08-DEC-05
UK1007204.9Microneedle Array O¿Mahony C. and Moore, A.C.29-APR-10
UK 1007207.2Microneedle kits for vaccine delivery Moore A.C., Carey J.B., Pearson F., McGrath, M., Crean A., Hill A.V.S and O¿Mahony, C.,29-APR-10
GB1107642.9Method for making dissolvable microneedle patches A. Vrdoljak, A. Moore09-MAY-11
GB1019577.4Method to prepare dissolvable microneedles. Crean A., O’Mahony, C. McGrath, M., Vrdoljak, A. Moore A.C18-NOV-10

Conference Contributions

YearPublication
(2014)Vaccines2014,
Anne Moore (2014) Probing the effect of skin-based immunization using Pseudotyped virus-based assays. [Invited Oral Presentation], Vaccines2014, O2 London UK , 20-OCT-14 - 22-OCT-14. [Details]
(2014)The Modes of Action of Vaccine Adjuvants,
O. Flynn, E. Allen, K. Dillane, A. Crean , E. Norton and A. Moore (2014) Immunogenicity of dmLT Adjuvanted Vaccines in ImmuPatch Dissolvable Microneedle. [Oral Presentation], The Modes of Action of Vaccine Adjuvants, Seattle, WA, USA , 08-OCT-14 - 13-OCT-14. [Details]
(2014)World Vaccine Congress,
E. Allen, O. Flynn, K. Dillane, C. O’Mahony, A. Crean and A. Moore (2014) Immunogenicity and Stability of Trivalent Inactivated Influenza Virus Vaccine in ImmuPatch Dissolvable Microneedles. [Poster Presentation], World Vaccine Congress, Sheraton, Brussels , 13-OCT-14 - 15-OCT-14. [Details]
(2014)Third International Conference on Microneedles,
Sonja Vucen, Gordana Vuleta, Jela Milic, Abina Crean, Anne Moore, Nenad Ignjatovic, Dragan Uskokovic (2014) Short-term storage stability of dissolvable microneedles containing ketoprofen-loaded polymeric nanoparticles. [Poster Presentation], Third International Conference on Microneedles, Baltimore, MD, USA , 19-MAY-14 - 21-MAY-14. [Details]
(2014)Third International Conference on Microneedles,
K. Dillane, T. Aherne, A. Offroy, C. O’Mahony, A. Crean and A. Moore (2014) Assessment of the physical stability of trehalose dissolvable microneedles in an ambient temperature and humidity environment. [Poster Presentation], Third International Conference on Microneedles, Baltimore, MD , 19-MAY-14 - 21-MAY-14. [Details]
(2014)Third International Conference on Microneedles, Baltimore,
O. Flynn, E. Allen, K. Dillane, A. Quinlan, C. O’Mahony, A. Crean, E. Norton and A. Moore (2014) Immunogenicity of Adjuvanted Vaccines in ImmuPatch Dissolvable Microneedle Patches in Mice. [Poster Presentation], Third International Conference on Microneedles, Baltimore, Baltimore, MD, USA , 19-MAY-14 - 21-MAY-14. [Details]
(2014)Third International Conference on Microneedles,
Anne Moore (2014) Development of ImmuPatch Microneedle Systems for Immunization Programs. [Invited Oral Presentation], Third International Conference on Microneedles, Baltimore, MD, USA . [Details]
(2014)Third International Conference on Microneedles,
C. O’Sullivan, M.A.P. McAuliffe, E. O’Neill, A. Moore, A. Crean (2014) Raman Spectroscopy as a Qualitative Tool to Characterise Solid State Properties of Drug-Loaded Dissolvable Microneedles. [Poster Presentation], Third International Conference on Microneedles, Baltimore, MD, USA , 19-MAY-04 - 21-MAY-14. [Details]
(2014)Third International Conference on Microneedles,
E. Allen, O. Flynn, K. Dillane, C. O’Mahony, A. Crean and A. Moore (2014) Immunogenicity and Stability of Trivalent Inactivated Influenza Virus Vaccine in ImmuPatch Dissolvable Microneedles. [Poster Presentation], Third International Conference on Microneedles, Baltimore, MD, USA , 19-MAY-14 - 21-MAY-14. [Details]
(2013)“The pig as model in human vaccine development,
Anne Moore (2013) Pig as a model for intradermal vaccination. [Invited Lectures (Workshops)], “The pig as model in human vaccine development, Central Veterinary Institute in Lelystad, NL , 20-SEP-03. [Details]
(2013)The pig as model in human vaccine development,
Anne Moore (2013) Pig as a model for intradermal vaccination. [Invited Oral Presentation], The pig as model in human vaccine development, Leylstad, NL . [Details]
(2013)Irish Medical Device Association (IMDA) and Enterprise Ireland hosted “R&D Funding Opportunities through Horizon 2020,
Anne Moore (2013) ImmuPatch. [Invited Oral Presentation], Irish Medical Device Association (IMDA) and Enterprise Ireland hosted “R&D Funding Opportunities through Horizon 2020, Galway . [Details]
(2012)Second International Conference on Microneedles,
Anne Moore (2012) Co-Chair of Conference. [Conference Organising Committee Chairperson], Second International Conference on Microneedles, Cork, Ireland . [Details]
(2012)Sharebiotech: Fostering Open Innovation in Biotechnology,
Crean, A.M., Moore A.C., O'Mahony C. (2012) ImmuPatch: a skin-deep approach to vaccination and drug delivery. [Invited Oral Presentation], Sharebiotech: Fostering Open Innovation in Biotechnology, Pamplona , 10-MAY-12 - 11-MAY-12. [Details]
(2011)Skin Vaccine Summit,
Anne Moore; (2011) Development of Silicon and Dissolvable ImmuPatch Microneedle Devices for Vaccination. [Oral Presentation], Skin Vaccine Summit, Washington DC , 12-OCT-11 - 14-OCT-11. [Details]
(2011)PharmSciFair,
A Moore; (2011) Development of Silicon and Dissolvable ImmuPatch Microneedle Devices for Vaccination. [Invited Oral Presentation], PharmSciFair, Prague , 11-OCT-11 - 14-OCT-11. [Details]
(2011)Insights into Successful Translational Research,
Anne Moore (2011) SFI/HRB/MMI organised event. [Invited Oral Presentation], Insights into Successful Translational Research, Dublin . [Details]
(2011)Insights into Successful Translational Research,
Anne Moore (2011) SFI/HRB/MMI organised national meeting. [Invited Seminars/Guest Lectures], Insights into Successful Translational Research, Dublin , 29-NOV-11. [Details]
(2010)First International Conference on Microneedles,
Pearson F.E., Reyes-Sandoval A.,. O'Mahony C, Moore A.C., Hill A.V.S, ; (2010) Delivery of Recombinant Adenoviral Vector Malaria Vaccines by ImmuPatch Induces Protective CD8+ T Cell Mediated Immunity Against Parasite Challenge. [Poster Presentation], First International Conference on Microneedles, Atlanta, Georgia, , 24-MAY-10 - 26-MAY-10. [Details]
(2010)Perspectives in Percutaneous Penetreation,
O'Mahony C, Blake A., Scully J., O'Brien J. and Moore A.C; (2010) Silicon Microneedles for Painless Percutaneous Penetration. [Poster Presentation], Perspectives in Percutaneous Penetreation, La Grande Motte, France , 06-APR-10 - 10-APR-10. [Details]
(2009)Modern Vaccines adjuvants and Delivery Systems,
Carey J.B., Gilbert S.C., Vrdoljak, A., Hill A.V.S and Moore A.C; (2009) T cell inducing flu vaccines; Protective Efficacy and Strain Specificity. [Poster Presentation], Modern Vaccines adjuvants and Delivery Systems, Vienna, Austria , 28-OCT-09 - 30-OCT-09. [Details]
(2009)European Congress of Immunology,
Carey J.B., Gilbert S.C., A., Hill A.V.S and Moore A.C. ; (2009) Immunogenicity and protective efficacy of a viral vectored candidate human pandemic influenza vaccine. [Oral Presentation], European Congress of Immunology, European Congress of Immunology, Berlin, Germany, , 13-SEP-09 - 16-SEP-09. [Details]
(2009)2nd Annual Oxford Avian Influenza Conference, BirdFlu2009,
Carey J.B., Gilbert S.C., A., Hill A.V.S and Moore A.C ; (2009) Pre-clinical assessment of a candidate T cell inducing viral vectored vaccine for human influenza viru. [Oral Presentation], 2nd Annual Oxford Avian Influenza Conference, BirdFlu2009, Oxford, UK , 10-SEP-09 - 11-SEP-09. [Details]
(2007)Unknown,
Moore, A. C. ; (2007) Anti-CD25 Antibody Enhancement of Vaccine-induced immunogenicity; translation form Mouse to Primates. [Oral Presentation], Unknown, Cork, Ireland , 01-JUN-07 - 01-JUN-07. [Details]
(2007)Vaccine Induced Immunity to Fight Disease,
Moore, A. C. ; (2007) unknown. [Oral Presentation], Vaccine Induced Immunity to Fight Disease, Biochemistry Dept., UCC, , 01-APR-07 - 01-APR-07. [Details]
(2009)Big Ideas Showcase 2009,
Moore, A. C.,Carey, J. B..,Vrdoljak, A.,McGrath, M. G.,Crean, A.,O'Mahony, C. (2009) ImmuPatch: Innovative Solutions to Vaccine Delivery Barriers. [Oral Presentation], Big Ideas Showcase 2009, Dublin, Ireland . [Details]
(2007)T cell Inducing Influenza Virus Vaccines,
Moore A.C., Gallimore A., Draper S., Watkins K.R., Gilbert S.C. and Hill A.V.S. ; (2007) unknown. [Oral Presentation], T cell Inducing Influenza Virus Vaccines, University of Johannesburg , 01-OCT-07 - 01-OCT-07. [Details]
(2006)Malaria and TB Vaccines; Modulating, Protective and Regulatory T cell responses,
Moore, A. C. ; (2006) Control of anti-tumoral and anti-infectious immune responses by Regulatory T cell subsets: potential clinical applications. [Oral Presentation], Malaria and TB Vaccines; Modulating, Protective and Regulatory T cell responses, Annecy, France , 01-SEP-06 - 01-SEP-06. [Details]
(2005)Virus Vector Based Vaccines,
Moore, A. C. ; (2005) unknown. [Oral Presentation], Virus Vector Based Vaccines, University of Nottingham , 01-APR-05 - 01-APR-05. [Details]
(2005)Assaying Potency of Novel Vaccines,
Moore, A. C. ; (2005) Potency of Poxviral Based Vectors for Malaria and TB vaccines. [Oral Presentation], Assaying Potency of Novel Vaccines, NIH, Bethesda, MD , 01-OCT-05 - 01-OCT-05. [Details]
(2005)Tropical Network Meeting,
Moore, A. C. ; (2005) Improving Immunogenicity by Deregulating Malaria Vaccines. [Oral Presentation], Tropical Network Meeting, Kilifi, Kenya , 01-SEP-05 - 01-SEP-05. [Details]
(2005)British Council, INYS meeting,
Moore, A. C. ; (2005) Progress in Virus Vector based Malaria and TB vaccines. [Oral Presentation], British Council, INYS meeting, Dunedin, New Zealand , 01-MAR-05 - 01-MAR-05. [Details]
(2004)Keystone Symposium: Rational Design of Vaccines and Immunotherapeutics,
Moore, A. C. ; (2004) PRE-EXISTING FOWLPOX IMMUNITY IS LESS INHIBITORY TO HETEROLOGOUS PRIME-BOOST VACCINE STRATEGIES COMPARED TO ANTI-MVA IMMUNITY. [Oral Presentation], Keystone Symposium: Rational Design of Vaccines and Immunotherapeutics, Keystone Resort, Keystone, Colorado , 01-MAR-04 - 01-MAR-04. [Details]
(2004)University of Wales College of Medicine BSI seminar series,
Moore, A. C. ; (2004) Prime Boost Malaria Vaccines. [Oral Presentation], University of Wales College of Medicine BSI seminar series, Wales , 01-DEC-04 - 01-DEC-04. [Details]
(2004)British Society for Immunology,
Moore, A. C. ; (2004) Progress in Malaria and TB vaccines; improved de-regulated vaccine strategies. [Oral Presentation], British Society for Immunology, Harrogate, UK , 01-DEC-04 - 01-DEC-04. [Details]

Disclosures

 TitleInventorSubmitted
T cell inducing influenza virus vaccines. Gilbert S.C., Moore A.C., and Hill A.V.S28-SEP-07
Method of fabrication and composition of dissolvable microneedles. Crean A, McGrath M., Vrdoljak A, O¿Mahony C. and Moore A.C Submitted April 201021-APR-10
Method of fabrication and composition of dissolvable microneedle patches Vrdoljak A, Crean A, McGrath M., O¿Mahony C. and Moore A.C21-APR-10
Methods of modulating cell surface expression of the IL-2 receptor Dev K.K., Moore A.C24-JUN-08

Committees

 CommitteeFunctionFrom / To
School of Pharmacy, Research and Graduate Studies Committee Chair2008 /
School of Pharmacy, Research Quality Review Committee Vice-Chair2008 / 2009
School of Pharmacy, Quality Review Committee Vice-Chair2008 / 2009
College of Medicine and Health Research Committee Member2009 /
UCC Genetically Modified Biological Organisms Committee. Member2009 /
College of Medicine and Health Graduate School Committee Member2010 /

Employment

 EmployerPositionFrom / To
University College Cork Lecturer01-JAN-07 /
University of Oxford Senior Immunologist01-JAN-02 / 01-JAN-06
University of Oxford Postdoctoral Associate01-JAN-01 / 01-JAN-02
University of Michigan Postdoctoral Associate01-JAN-98 / 01-JAN-01
The Wistar Institute, Philadelphia, USA Postdoctoral Scientist01-SEP-97 / 31-JUL-98

Consultancy

 ClientDescription
Grand Challenge for Global Health research team, Oxford University

Outreach Activities

 Description

Erasmus Co-ordinator, School of Pharmacy (Dec 2007-present).


UCC Science Society seminar: A Skin-deep Approach to Vaccines, UCC, 18th Nov. 2014

Journal Activities

 JournalRoleTo / From
Plos One Member of Editorial Board01-MAY-14 -
Vaccine Referee-
Expert Review Of Vaccines Referee-
Immunological Reviews Referee-
J Control Release Referee01-JAN-12 - 31-DEC-15

Teaching Interests

PT6401: Pharmacology for M.Sc. in Pharmaceutical Technology and Quality Systems
PT4447; Advanced Pharmacology
PT3447; Clinical Pharmacology
PF4004: lectures on animal ethics
PT2447: Molecular Pharmacology
PT1445: Foundation Pharmacology

Recent Postgraduates

 Graduation YearStudent NameInstitutionDegree TypeThesis Title
2012Marie McGrath NUI (UCC)Ph.D. (NUI)Design and characterisation of Microneedles for Percutaneous Vaccine Delivery

Current Postgraduate Students

 StudentDegree Type
Allen Evin Anthony Doctoral Degree
Marshall Sarah Masters Degree by Research

Modules Taught

 Term (ID))TitleLinkSubject
2015Pharmacology PT6401Pharmacology
2015Molecular Pharmacology PT2447Molecular Pharmacology
2015Foundation Pharmacology PT1445Foundation Pharmacology
2015Advanced Pharmacology and Veterinary Pharmacology PT4447Advanced Pharmacology and Veterinary Pharmacology